Ligand Pharma (LGND) PT Lifted to $127 at Roth Capital Following Q1 and as Pipeline Expands
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Cantor Fitzgerald Reiterate Hold Following Ligand Pharma's (LGND) Strong Q1
May 13, 2015 7:23 AM EDTCantor Fitzgerald reiterate a Hold rating on Ligand Pharma (NASDAQ: LGND), and raise the price target to $86.00 (from $82.00), following a strong 1Q. LGND reported revenues of $14.6M, and an adjusted non-GAAP EPS of $0.33. Coming out ahead of FactSet consensus of $13.5M revenue and $0.27 EPS.... More
Ligand Pharma (LGND) Tops Q1 EPS by 6c
May 11, 2015 8:31 AM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.33, $0.06 better than the analyst estimate of $0.27. Revenue for the quarter came in at $14.6 million versus the consensus estimate of $13.5 million.
Ligand Pharma sees FY2015 EPS of $2.14-$2.18, versus the consensus of $2.13. Ligand Pharma sees FY2015... More
